Advertisement
Mr. Moore brings over twenty years of sales, marketing, and businessdevelopment experience in the pharmaceutical industry to his new role atTranscept. He has demonstrated exceptional results as a senior member ofmanagement teams at Organon Biosciences (now Schering Plough), Wyeth, Johnson& Johnson, and Eli Lilly. His contributions include building multi-billiondollar brands such as Prozac(R), Zyprexa(R), Risperdal(R), and Effexor XR(R).Immediately prior to joining Transcept, Mr. Moore served as Vice President ofthe Neuroscience Therapeutic Area for Organon Biosciences and was responsiblefor the creation and building of the Neuroscience Business Unit. Beforejoining Organon Biosciences, Mr. Moore served as Vice President, U.S.Marketing, Effexor XR(R) as well as Vice President, Global Strategy DepressionPortfolio for Wyeth Pharmaceuticals. Mr. Moore holds a BS in Pharmacy from theUniversity of Florida, a BA in Chemistry from the University of South Floridaand has taken additional executive level courses at the Wharton and KelloggSchools of Business.
Advertisement
"I am delighted to join the Transcept management team at such an excitingtime in the company's development," said Mr. Moore. "Intermezzo(R) has thepotential to become an innovative low dose solution for insomnia patients whowake up in the middle of the night and want to go back to sleep quickly.Intermezzo(R) will enable patients to treat their middle of the nightawakening only when it occurs, rather than having to take a high dose, 8 hourmedication at bedtime. I'm thrilled to be a part of a team dedicated todeveloping and commercializing innovative neuroscience-based products."
Susan Koppy has over 20 years of experience in marketing and businessdevelopment in the biopharmaceutical industry and has lived and worked in theU.S., Europe and Japan. She has negotiated a number of major multi-billiondollar agreements and is a frequent speaker on business development issues.Prior to joining Transcept, Susan Koppy served as Senior Vice President,Business and Corporate Development at Idenix Pharmaceuticals, Inc.Previously, Ms. Koppy was Vice President of Strategy and Business Developmentat Applied Biosystems, Inc. (ABI) with responsibility for evaluation andpursuit of licensing and acquisition opportunities. Before joining ABI, Ms.Koppy served as the Director of Business Development for NovartisPharmaceuticals Corporation where she was responsible for global businessdevelopment opportunities in Infectious Diseases and was a key contributor tothe formation of the strategic alliance between Idenix and Novartis. Ms.Koppy also served as the Head of Commercial and Business Intelligence forNovartis Pharma AG and worked in Early Commercial Development with theRespiratory and Immunology therapeutic areas. She holds a bachelor's degreein Genetics and Cell Biology from the University of Minnesota.
"I am excited to join a team of executives with extensive experience inboth pharmaceutical development and commercialization," said Ms. Koppy. "Ilook forward to leading the T
